Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. - Wikidata - wikimedia - TriplyDB

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

http://www.wikidata.org/entity/Q38118900

about

Potential use of histone deacetylase inhibitors in cancer therapy Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study Histone deacetylase enzymes as drug targets for the control of the sheep blowfly, Lucilia cuprina Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.Caffeic acid derivatives, analogs and applications: a patent review (2009-2013).Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.Multiple myeloma: managing a complex blood cancer.HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo.Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.SAHA (Vorinostat) Corrects Inhibitory Synaptic Deficits Caused by Missense Epilepsy Mutations to the GABAA Receptor γ2 Subunit.Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

P2860

Q26769594-02B368F7-ADD3-416F-89F0-09C9DCDC0CCF Q28818731-52947D2F-BEEE-4ED9-A0A0-E20CFC7AC9B0 Q33960142-8D656A36-2B13-41E3-975C-A0B65B88B2FB Q36211604-EF57B99A-6D16-4BE1-9843-EAA1C20A3E44 Q36841513-9913B6C4-67EB-43AC-A19E-AF74E9FEB3AE Q36946516-2B4F437B-E293-4B0F-A123-E6BDAF278405 Q37144949-22D8837A-3E06-49E7-8E38-6243401CD894 Q37199772-B6D7D97F-8219-4CF6-B669-7BA62F23173D Q38139309-FC9A39E0-8198-4F79-9745-69C5AA96EAB9 Q38256950-C29D315B-403D-4CA5-B63D-ABAB42161450 Q38840351-09C9C871-41AE-48F3-A68D-DBA4F3DF8FC0 Q38951283-1430E795-0150-4A03-9197-13A12ADE4265 Q40515496-05409D13-E14D-4571-ABCA-A6D2ED8EDDEF Q40690632-CC35A56A-0289-476F-BC22-5F5D64C7A07D Q42328146-54CCFEFC-1C06-4FD4-AA91-100848F36CC0 Q44315979-FA25AC49-EE5E-4CF5-A4E5-1E6CDBDB28CB Q47633998-857E596A-DF38-4AE2-9666-35ED56A8EF64 Q47793104-E7DA318E-5A21-450A-BD80-69F0CD024935 Q47843990-8A6CAC9F-5B83-4A7F-A21B-962EA1C777F1 Q52599717-76F25C62-104F-48A5-8A10-538455A62D7A Q58130496-CCD7D69B-4DE8-4686-B95B-A5805F3272D4

P2860

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

http://www.wikidata.org/entity/Q38118900

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

@en

type

label

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

@en

prefLabel

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

@en

P1433

Q38118900-0FE6E171-FC95-4205-8910-E8B84EFDE5C2

P1476

Q38118900-E57380DD-2E04-4470-9DE1-4D74BFBC9DDC

P2093

Q38118900-0C5F780E-2C2F-4234-86E2-52CEC29DEEAA

Q38118900-0EDD1D2D-3025-409E-9126-20ED4CEDB3DB

Q38118900-36F17D47-3CFB-4079-B698-CA0F599AE052

Q38118900-AA402DDF-8074-456A-B4E7-0A6FC81827B7

Q38118900-BC623E94-6D8B-4A6A-B8BD-96E067FE0B61

Q38118900-BE5283C6-20B3-4531-9E39-E32955209707

P2860

Q38118900-1A442878-B882-47CA-B067-ECE92487C99D

Q38118900-2D09E4C3-87B1-4E98-8DBC-872B79326413

Q38118900-2E75F398-7ED9-4FC5-9163-8CBD5D92B6FD

Q38118900-30714140-BCEE-4A7F-AE12-39202AF25D84

Q38118900-327A42FB-CA21-4A13-B5F7-0BA969721C6F

Q38118900-3DAB6735-C9BA-457E-BD00-66D24A61753B

Q38118900-44BBAE9F-1026-4E4A-A4EF-AFC954062F49

Q38118900-664243E3-8DF8-46E2-AD62-E386C812B6C4

Q38118900-71038F25-2FB1-4773-AC17-8B24409DD685

Q38118900-7DE2FFF1-754E-4E44-87A5-F865C74796B4

P2888

Q38118900-8419AC1F-4278-4E55-B73D-AFC9635F2CFA

P304

Q38118900-33553206-C353-45C3-8A50-BCAFE94B7D1D

P31

Q38118900-805F5130-85BC-4F83-82BB-5E1CECC910CE

P356

Q38118900-2EDC7293-D81E-498E-9D98-A509DBA38317

P433

Q38118900-F9CF9AAC-C29F-4F19-9C75-12C6FC649C48

P478

Q38118900-16E7EBE6-C20D-49CD-98E0-D4DDF703CB62

P577

Q38118900-A54A9AB4-2E98-4D94-8363-05C0C7541FC6

P6179

Q38118900-A7259016-EB1D-4E9F-8178-E2A8CC2B4AEF

P698

Q38118900-F7A8F307-A14F-4E88-A0C7-238D02AE2A52

P921

Q38118900-EC847BC9-7B6A-4457-BAF5-CB04A1428CF8

Q38118900-FB9D3AFC-D621-4F60-8E83-1550A9A6D2C6

P356

S00280-013-2220-Z

P1433

Cancer Chemotherapy and Pharmacology

P1476

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

@en

P2093

Eric H Rubin

http://www.w3.org/2001/XMLSchema#string

Evan J Friedman

http://www.w3.org/2001/XMLSchema#string

John A Wagner

http://www.w3.org/2001/XMLSchema#string

Marian Iwamoto

http://www.w3.org/2001/XMLSchema#string

Nancy G B Agrawal

http://www.w3.org/2001/XMLSchema#string

Punam Sandhu

http://www.w3.org/2001/XMLSchema#string

P2860

HDAC6 is a microtubule-associated deacetylase

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Anticancer activities of histone deacetylase inhibitors

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.

P2888

s00280-013-2220-z

P304

493-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2220-Z

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1041009341

http://www.w3.org/2001/XMLSchema#string

P698

23820962

http://www.w3.org/2001/XMLSchema#string

P921